Search - tctmd.com

Displaying 1 - 20 of 96

Sort: Relevancy | Date

News Conference News AHA 2025

Olezarsen Cuts Triglycerides, Pancreatitis Risk in Severe Hypertriglyceridemia

Michael O'Riordan

November 14, 2025

News Conference News AHA 2025

Stopping DOACs After Successful AF Ablation Feasible in Low-risk Patients: OCEAN

Michael O'Riordan

November 08, 2025

News Conference News AHA 2025

Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV

Michael O'Riordan

November 08, 2025

News Conference News AHA 2025

CRISPR-Cas9 Gene-Editing Therapy Shows Early Promise for Dyslipidemia

Todd Neale

November 08, 2025

News Conference News EuroPCR 2025

Lower MACE Risk With FFR- vs Angio-Guided PCI in AS Patients: FAITAVI

L.A. McKeown

May 22, 2025

News Conference News ACC 2025

FAIR-HF2: Another IV Iron Trial Fails to Impact Hard Endpoints

L.A. McKeown

April 03, 2025

News Conference News AHA 2024

Two Lp(a)-Lowering Therapies Clear Bar in KRAKEN and ALPACAR-360

Michael O'Riordan

November 18, 2024

News Conference News AHA 2024

ARNI Lessens Anthracycline Cardiotoxicity in High-Risk Patients: SARAH

Caitlin E. Cox

November 18, 2024

News Conference News AHA 2024

Lifestyle and Risk Factors Matter for AF Burden—Metformin May Not: TRIM-AF

Shelley Wood

November 18, 2024

News Conference News AHA 2024

Audits and Feedback Aid Pharmacist-Driven HF Care: PHARM-HF A&F

Michael O'Riordan

November 16, 2024

News Conference News AHA 2024

Rivaroxaban Doesn’t Cut Cognitive Decline, Stroke, or TIA in Younger AF Patients

Shelley Wood

November 16, 2024

SUMMIT: Tirzepatide ‘Huge Win’ for HFpEF Patients With Obesity

News Conference News AHA 2024

SUMMIT: Tirzepatide a ‘Huge Win’ for HFpEF Patients With Obesity

Michael O'Riordan

November 16, 2024

News Conference News VIVA 2024

It’s Been 1 Year Since Medicare’s NCD for Carotid Stenting: What Now?

L.A. McKeown

November 14, 2024

News Conference News TCT 2024

Colchicine Surprise: No Help Post-MI, Large CLEAR SYNERGY Trial Shows

Michael O'Riordan

October 29, 2024

News Conference News HFSA 2024

FINEARTS-HF: New Analyses Ask, Who Benefits Most From Finerenone?

Michael O'Riordan

October 02, 2024

News Conference News NY Valves 2024

Polymer Mitral Valve Shows Well Early, but Long-term Data Key

Michael O'Riordan

June 12, 2024

News Conference News ESC Heart Failure 2024

SEQUOIA-HCM: Aficamten Boosts Exercise Capacity in Obstructive HCM

Michael O'Riordan

May 13, 2024

News Conference News ACC 2024

Triglyceride-Lowering Therapies Provide Favorable Outcomes in Early Testing

Michael O'Riordan

April 12, 2024

$Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC$

News Conference News ACC 2024

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Michael O'Riordan

April 08, 2024

News Conference News AHA 2023

Placebo-Controlled ORBITA-2 Shows PCI Eases Symptoms in Stable Angina

Michael O'Riordan

November 11, 2023

Advertisement

Olezarsen Cuts Triglycerides, Pancreatitis Risk in Severe Hypertriglyceridemia

Stopping DOACs After Successful AF Ablation Feasible in Low-risk Patients: OCEAN

Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV

CRISPR-Cas9 Gene-Editing Therapy Shows Early Promise for Dyslipidemia

Lower MACE Risk With FFR- vs Angio-Guided PCI in AS Patients: FAITAVI

FAIR-HF2: Another IV Iron Trial Fails to Impact Hard Endpoints

Two Lp(a)-Lowering Therapies Clear Bar in KRAKEN and ALPACAR-360

ARNI Lessens Anthracycline Cardiotoxicity in High-Risk Patients: SARAH

Lifestyle and Risk Factors Matter for AF Burden—Metformin May Not: TRIM-AF

Audits and Feedback Aid Pharmacist-Driven HF Care: PHARM-HF A&F

Rivaroxaban Doesn’t Cut Cognitive Decline, Stroke, or TIA in Younger AF Patients

SUMMIT: Tirzepatide a ‘Huge Win’ for HFpEF Patients With Obesity

It’s Been 1 Year Since Medicare’s NCD for Carotid Stenting: What Now?

Colchicine Surprise: No Help Post-MI, Large CLEAR SYNERGY Trial Shows

FINEARTS-HF: New Analyses Ask, Who Benefits Most From Finerenone?

Polymer Mitral Valve Shows Well Early, but Long-term Data Key

SEQUOIA-HCM: Aficamten Boosts Exercise Capacity in Obstructive HCM

Triglyceride-Lowering Therapies Provide Favorable Outcomes in Early Testing

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Placebo-Controlled ORBITA-2 Shows PCI Eases Symptoms in Stable Angina

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content